Product Name: Ecnoglutide
CAS No: 2459531-73-6
Purity: 95%
Molar Mass: 4284.76
Chemical Formula: C194H304N48O61
Synonyms: XW003, KM6YM7L8LH
Storage: Store at -20℃
Sequence: HVEGTFTSDVSSYLEEQAAREFIK-(AEEA-AEEA-{γ-Glu}-C18 diacid)-WLVRGRG
Target: GLP-1 RA
Application: Ecnoglutide (CAS: 2459531-73-6) is a novel GLP-1 peptide analog developed with the aim of improving stability, efficacy, and manufacturing feasibility. Through modifications to the GLP-1 peptide, particularly acylation at lysine position 30, Ecnoglutide was chosen for further development due to its favorable properties. Unlike semaglutide, it encodes valine at position 8, promoting cAMP bias and simplifying manufacturing processes by allowing synthesis from recombinant DNA without chemical conjugation. In preclinical studies, Ecnoglutide demonstrated similar potency to semaglutide in inducing cAMP and β-arrestin recruitment but exhibited more bias towards cAMP signaling, potentially enhancing its efficacy. Ecnoglutide showed significantly higher efficacy compared to semaglutide in preclinical models, particularly in blood glucose control and weight loss. Phase 1 studies in healthy volunteers confirmed its safety and tolerability with once-weekly subcutaneous dosing, and its pharmacokinetics were similar to semaglutide. Notably, Ecnoglutide displayed improved stability in simulated gastrointestinal fluid, suggesting potential for oral formulation development. Overall, Ecnoglutide shows promise as a therapeutic option for type 2 diabetes mellitus (T2DM) and obesity, with ongoing clinical trials supporting its continued development and evaluation.
Reference:
